| Summary: | Chengxin Luan,1,* Zixue Yang,2,* Baoan Chen1 1Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, 2State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, People’s Republic of China *These authors contributed equally to this work Abstract: MicroRNAs (miRNAs), a new class of noncoding RNAs, which can hybridize to target messenger RNAs and regulate their expression posttranscriptionally, express differentially in distinct stages of lymphopoiesis and influence the direction of lymphoid precursor maturation. Hence, there is aberrant expression of miRNAs involved in malignant lymphopoiesis, and these aberrations can be used as signatures of acute lymphoblastic leukemia (ALL) with different subtypes. In addition, changes in the expression of several miRNAs may have functional relevance with leukemogenesis or drug resistance. As a result, the reversal of the expression of these miRNAs may alleviate the disease to some extent and improve clinical outcomes. However, among the studies of miRNAs, there are still some problems that need to be solved to understand the function of miRNAs in ALL more thoroughly. Keywords: ALL, microRNA, lymphopoiesis, molecular diagnosis, lymphoid malignant, molecular therapy
|
|---|
